Overcoming Resistance of Human Non-Hodgkin’s Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors

Patients with B-cell non-Hodgkin’s lymphoma (B-NHL) who fail to respond to first-line treatment regimens or develop resistance, exhibit poor prognosis. This signifies the need to develop alternative treatment strategies. CD19-chimeric antigen receptor (CAR) T cell-redirected immunotherapy is an attr...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres-Collado, Antoni Xavier, Jazirehi, Ali R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025421/
https://www.ncbi.nlm.nih.gov/pubmed/29904021
http://dx.doi.org/10.3390/cancers10060200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025421/
https://www.ncbi.nlm.nih.gov/pubmed/29904021
http://dx.doi.org/10.3390/cancers10060200

Ejemplares similares